Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study
- PMID: 17318527
- DOI: 10.1007/s00228-007-0267-7
Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study
Abstract
Objective: The pharmacokinetics of nimodipine following enteral administration in the early phase after subarachnoid haemorrhage (SAH) has not been described. If a sufficient absorption could be achieved with enterally administered nimodipine, this would be more feasible dosage form and result in a significant reduction in pharmaceutical costs given that the parenteral formulation of nimodipine currently used is tenfold more expensive than the enteral formulation.
Methods: This was a pilot study in which 17 patients with aneurysmal SAH were randomly assigned to receive nimodipine within 24 h after initial bleeding either as an 60 mg tablet/suspension at 4-h intervals, or as a continuous intravenous infusion of 2 mg/h. Serum nimodipine concentrations were measured during the 4 h following the first dose, and at 24 and 72 h on a validated gas chromatography mass spectrometer (GC-MS).
Results: Nimodipine AUC values (expressed in mug min/ml) were lower in the eight SAH patients receiving enteral nimodipine [AUC(0-4) range: 0.13-5.4 (median: 0.32); AUC(24-28) range: 0.16-6.1 (0.71); AUC(72-76) range: 0.47-20.6 (1.9)] than in the nine patients receiving a continuous intravenous infusion of nimodipine [AUC(0-4) range: 2.4-4.9 (3.4), p=0.059; AUC(24-28) range: 4.7-10.3 (7.3), p=0.001; AUC(72-76) range: 3.4-8.6 (6.9), p=0.001]. In three of five good-grade SAH patients receiving nimodipine tablets the AUC values were comparable to those of the intravenous administration, but in two good-grade patients with tablets and in all three poor-grade (Hunt&Hess, grade IV) SAH patients receiving the suspension, the rate and extent of nimodipine absorption was negligible.
Conclusion: This pilot study indicates that the rate and extent of nimodipine absorption following enteral administration in some acute SAH patients could be negligible, and this may particularly be the case in patients with a decreased level of consciousness.
Similar articles
-
Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage.Acta Neurochir (Wien). 2015 May;157(5):763-7. doi: 10.1007/s00701-015-2369-9. Epub 2015 Feb 21. Acta Neurochir (Wien). 2015. PMID: 25701099 Clinical Trial.
-
Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.Neurocrit Care. 2019 Aug;31(1):32-39. doi: 10.1007/s12028-019-00676-w. Neurocrit Care. 2019. PMID: 30725331
-
A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage.World Neurosurg. 2012 Jul;78(1-2):101-9. doi: 10.1016/j.wneu.2011.09.030. Epub 2011 Nov 1. World Neurosurg. 2012. PMID: 22120252 Clinical Trial.
-
[Treatment following aneurysmal subarachnoid hemorrhage].Pharm Unserer Zeit. 2005;34(5):412-6. doi: 10.1002/pauz.200500140. Pharm Unserer Zeit. 2005. PMID: 16180364 Review. German. No abstract available.
-
Traumatic subarachnoid haemorrhage.Hosp Med. 1999 Jul;60(7):497-9. doi: 10.12968/hosp.1999.60.7.1155. Hosp Med. 1999. PMID: 10605541 Review.
Cited by
-
Nimodipine Pharmacokinetic Variability in Various Patient Populations.Drugs R D. 2020 Dec;20(4):307-318. doi: 10.1007/s40268-020-00322-3. Drugs R D. 2020. PMID: 32902829 Free PMC article.
-
Nimodipine systemic exposure and outcomes following aneurysmal subarachnoid hemorrhage: a pilot prospective observational study (ASH-1 study).Front Neurol. 2024 Jan 5;14:1233267. doi: 10.3389/fneur.2023.1233267. eCollection 2023. Front Neurol. 2024. PMID: 38249736 Free PMC article.
-
Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage.Neurocrit Care. 2023 Aug;39(1):104-115. doi: 10.1007/s12028-023-01760-y. Epub 2023 Jun 12. Neurocrit Care. 2023. PMID: 37308727 Free PMC article.
-
Pharmacotherapy variability and precision medicine in neurocritical care.Front Neurol. 2025 Jul 18;16:1630163. doi: 10.3389/fneur.2025.1630163. eCollection 2025. Front Neurol. 2025. PMID: 40757024 Free PMC article. Review.
-
The Nimodipine-Sparing Effect of Perioperative Dexmedetomidine Infusion During Aneurysmal Subarachnoid Hemorrhage: A Prospective, Randomized, Controlled Trial.Front Pharmacol. 2019 Aug 2;10:858. doi: 10.3389/fphar.2019.00858. eCollection 2019. Front Pharmacol. 2019. PMID: 31427968 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous